Comments
Commented by Juliane Zielonka on March 27th, 2025 | 07:10 CET
First Hydrogen, BYD, Amazon - How hydrogen, e-mobility, and quality control are transforming the economy
The global economy is changing, opening new doors for investors. Three companies are in the spotlight. First Hydrogen is attracting attention with hydrogen and small reactors as an energy source. The founding of the new subsidiary First Nuclear makes it clear: The energy future is being built here. Electric automaker BYD is pushing forward with all its might, aiming to produce 5.5 million vehicles in 2025 - the ambitious goal: To double sales outside of China. With production sites in the EU and other countries, the Company is cleverly avoiding possible tariffs and conquering new markets. Amazon remains a pioneer in its field and relies on green energy and quality: Wind and solar projects are being developed in Spain and Portugal. In addition, it is taking a tough line against brand counterfeiting – the fight against plagiarism in the marketplace has begun. Hydrogen, electric mobility, and quantum technology – these future drivers could fundamentally change existing industries. How exactly are these companies influencing tomorrow's world?
Read
Commented by Fabian Lorenz on March 27th, 2025 | 07:00 CET
Rocketing prices and takeover speculation! Steyr Motors, Evotec, and Defence Therapeutics!
Steyr Motors is now riding not only the defense wave but also the takeover wave. After the announcement of a cooperation with a Rheinmetall subsidiary, the niche stock has become a shooting star. However, the price has also come back just as quickly. The Austrians now want to grow aggressively through acquisitions. Without takeover speculation, the share price of Defence Therapeutics has already risen by over 60%. The biotech company is still inexpensive, is making progress in monetization, and could become an acquisition candidate. Evotec is currently out of steam. Analysts see significant downside potential and a chance of a turnaround.
Read
Commented by André Will-Laudien on March 26th, 2025 | 11:05 CET
Steyr, Hensoldt, Mutares, and thyssenkrupp sell, First Phosphate remains a gamechanger
The special fund of up to EUR 1 trillion has been approved. What seemed impossible before the election is now law. Federal President Steinmeier signed the amendment to the constitution at the weekend, thereby sealing the largest economic stimulus package in German economic history. Instead of celebrating, the DAX only rose briefly to 23,136 points, then the sell-off occurred according to the motto "Buy the Rumor, Sell the Fact". The hyped defense stocks could now suffer the same fate. A lot of imagination has been priced in here, but capacity expansion is proceeding slowly. Therefore, not all expectations will immediately translate into positive cash flows. A thorough analysis is needed!
Read
Commented by Armin Schulz on March 26th, 2025 | 07:10 CET
Volkswagen, European Lithium, BYD – Lithium as a winner in the crisis: Why analysts are predicting a rally despite the chaos
The global energy transition is catapulting lithium into the spotlight. As an indispensable raw material for batteries, the electrification of mobility and energy infrastructure has fueled demand enormously. But after the hype, prices plunged from record highs to below USD 10,000. Now, there are increasing signs of a trend reversal: Production cutbacks, a predicted demand explosion of around 20% this year, strategic investments by large corporations, and technological leaps in extraction could curb the oversupply. Is lithium on the verge of returning as the scarce "white gold"? The stage seems to be set for a revaluation of the market.
Read
Commented by Fabian Lorenz on March 26th, 2025 | 07:00 CET
ARMAMENTS and GOLD! Target prices are rising! Barrick Gold, Deutz, and Globex Mining!
The "Rambo Zambo" billions of Friedrich Merz continue to drive the Deutz share higher. After the solid annual figures, profit-taking seemed likely to set in for the engine manufacturer's shares, but this was misinterpreted! Yesterday, analysts again raised the target price significantly! The Globex Mining share is also performing strongly. The mining incubator is benefiting not only from the rising gold price, which remains solidly above the USD 3,000 mark. Will it crack the USD 3,500 mark soon? A deal has now been brokered with IAMGOLD. And what is Barrick Gold doing? After the recovery rally, it seems momentum has slowed. Now, a project is also being abandoned.
Read
Commented by Mario Hose on March 25th, 2025 | 15:40 CET
Buy recommendation for dynaCERT: GBC sees upside potential of over 300% to EUR 0.48!
Enter the green revolution: Cleantech stock with hydrogen potential! dynaCERT Inc. (ISIN: CA26780A1084 | TSX: DYA) is the focus of analyst Matthias Greiffenberger – and for good reason: The Canadian cleantech company is developing technologies to reduce emissions from combustion engines and could become a key player in the clean technology market in light of global decarbonization targets. In its latest analysis dated March 25, 2025, the renowned GBC AG issued a "Buy" recommendation – with a fair value of EUR 0.48 per share. This represents an upside of over 300% compared to the current share price! Read the report to find out more!
Read
Commented by Fabian Lorenz on March 25th, 2025 | 07:30 CET
Stocks in RALLY MODE: Deutz, Nel ASA with momentum! MiMedia taps into huge revenue potential with Walmart!
MiMedia has huge revenue potential and a favorable valuation. The cloud insider tip offers an exciting entry opportunity in Latin America after its partnership with Walmart. After a strong price increase at the turn of the year, the share is currently moving sideways – for now. Deutz's stock has shown how quickly a share price can rise in recent weeks. However, after the approximately 40% rally, the air is getting thinner, at least when looking at the figures for 2024. However, analysts think further price gains are possible. Nel has shown signs of life. The beleaguered hydrogen pioneer has landed a new major shareholder in Samsung and recently secured a major contract. Who will continue the rally?
Read
Commented by Stefan Feulner on March 25th, 2025 | 07:20 CET
BYD, 123fahrschule, RWE – Pure growth
The Chinese market leader for electric vehicles has defied all odds in recent weeks, shooting to a new all-time high despite the trade war and punitive tariffs. Rising sales numbers and continued growth are expected for BYD in the future. Likewise, the disruptor of the German driving school industry, 123fahrschule, is fully focused on expansion. With the placement of a convertible bond and the expansion of the board of directors, the path forward is clearly structured.
Read
Commented by Armin Schulz on March 25th, 2025 | 07:10 CET
Evotec, NetraMark, Novo Nordisk – From the lab to a golden digital future with artificial intelligence
The pharmaceutical industry is experiencing a revolution that is changing everything! Artificial intelligence is sweeping through laboratories and breaking with old habits. Algorithms scour billions of chemical structures in record time, uncovering hidden treasures of active ingredients. While years used to pass before a drug entered the testing phase, AI models are now picking up the pace. Heavyweights like AstraZeneca are in a neck-and-neck race with start-ups. Who will be the first to crack incurable diseases? The goal is to tailor therapies, revolutionize clinical studies, and save lives. Only those who use AI will remain competitive and be able to offer patients innovative drugs faster. The era of data-driven medicine has begun.
Read
Commented by Fabian Lorenz on March 25th, 2025 | 07:00 CET
Takeover speculation and buy recommendations: Buy Bayer, BioNTech, and BioNxt Solutions stock after a 150% rally?
While takeover speculations are currently on pause for Evotec, they are gaining momentum for BioNxt Solutions. The Company aims to achieve significant milestones in the next 60 days on the road to marketing its lead product for treating multiple sclerosis and expanding into the billion-dollar anti-aging market. Even after the 150% rally, BioNxt shares are not expensive. The BioNTech share has corrected sharply in 2025. However, positive analyst comments could now herald a turnaround. Will the oncology pipeline lead to a breakthrough? On the other hand, Bayer is facing a significant defeat in USD. Further billion-dollar payments are looming. Analysts remain skeptical.
Read